Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection
October 6, 2023
Gerd Heusch, Ioanna Andreadou, Robert Bell, Edoardo Bertero, Hans-Erik Botker, Sean M. Davidson, James Downey, Philip Eaton, Peter Ferdinandy, Bernard J. Gersh, Mauro Giacca, Derek J. Hausenloy, Borja Ibanez, Thomas Krieg, Christoph Maack, Rainer Schulz, Frank Sellke, Ajay M. Shah, Holger Thiele, Derek M. Yellon, Fabio Di Lisa
The present review summarizes the beneficial and detrimental roles of reactive oxygen species in myocardial ischemia/reperfusion injury and cardioprotection. In the first part, the continued need for cardioprotection beyond that by rapid reperfusion of acute myocardial infarction is emphasized. Then, pathomechanisms of myocardial ischemia/reperfusion to the myocardium and the coronary circulation and the different modes of cell death in myocardial infarction are characterized. Different mechanical and pharmacological interventions to protect the ischemic/reperfused myocardium in elective percutaneous coronary interventions and coronary artery bypass grafting, in acute myocardial infarction and in cardiotoxicity from cancer therapy are detailed. The second part keeps the focus on ROS providing a comprehensive overview of molecular and cellular mechanisms involved in ischemia/reperfusion injury. Starting from mitochondria as the main sources and targets of ROS in ischemic/reperfused myocardium, a complex network of cellular and extracellular processes is discussed, including relationships with Ca2+ homeostasis, thiol group redox balance, hydrogen sulfide modulation, crosstalk with NAPDH oxidases, exosomes, cytokines and growth factors. While mechanistic insights are needed to improve our current therapeutic approaches, advancements in knowledge of ROS-mediated processes indicate that detrimental facets of oxidative stress are opposed by ROS requirement for physiological and protective reactions. This inevitable contrast is likely to underlie unsuccessful clinical trials and limits the development of novel cardioprotective interventions simply based upon ROS removal.
IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action
September 13, 2021
Sandrine Lecour, Ioanna Andreadou, Hans Erik Bøtker, Sean M Davidson, Gerd Heusch, Marisol Ruiz-Meana, Rainer Schulz, Coert J Zuurbier, Péter Ferdinandy, Derek J Hausenloy, on behalf of the European Union-CARDIOPROTECTION COST ACTION CA16225
Acute myocardial infarction (AMI) and the heart failure (HF) which may follow are among the leading causes of death and disability worldwide. As such, new therapeutic interventions are still needed to protect the heart against acute ischemia/reperfusion injury to reduce myocardial infarct size and prevent the onset of HF in patients presenting with AMI. However, the clinical translation of cardioprotective interventions that have proven to be beneficial in preclinical animal studies, has been challenging. One likely major reason for this failure to translate cardioprotection into patient benefit is the lack of rigorous and systematic in vivo preclinical assessment of the efficacy of promising cardioprotective interventions prior to their clinical evaluation. To address this, we propose an in vivo set of step-by-step criteria for IMproving Preclinical Assessment of Cardioprotective Therapies (‘IMPACT’), for investigators to consider adopting before embarking on clinical studies, the aim of which is to improve the likelihood of translating novel cardioprotective interventions into the clinical setting for patient benefit.
Implications of oxidative stress and redox biochemistry for heart disease and cardioprotection – Free Radical Biology and Medicine Special Issue with EU-CARDIOPROTECTION COST Action CA16225
July 12, 2021
Edited by Andreas Daiber, Rainer Schulz, Derek Hausenloy, Ioanne Andreadou
In this Special Issue, which is a collaboration with the EU-CARDIOPROTECTION COST Action (CA16225 http://www.cardioprotection.eu/), we aim to highlight the redox biochemistry and oxidative stress underlying heart disease and cardioprotection as well as the existing research gaps. We will also emphasize emerging mechanisms impacting cardiac health and disease such as the circadian clock, the microbiome, epigenetic and neuronal/central pathways. Also therapeutic approaches and their impact on the redox biochemistry and oxidative stress of heart disease will be discussed in detail, including pre- and post- conditioning or physical exercise as non-drug-based therapies as well as modern cardiovascular drugs with pleiotropic antioxidant/anti-inflammatory properties. Special emphasis, although not exclusively, will be laid on the following points and how they are related to oxidative stress and redox biochemistry of heart disease:
(1) redox signalling in ischemia/reperfusion injury and heart failure
(2) discovery of new therapeutic targets and innovative strategies for cardioprotection against ischemia/reperfusion injury and heart failure
(3) testing the effects of combination therapy to target multiple signalling pathways both within and outside the cardiomyocyte
(4) investigating the effects of confounders (co-morbidities and co-medications) on cardioprotection.
Myocardial stunning and hibernation revisited
February 2, 2021
Unlike acute myocardial infarction with reperfusion, in which infarct size is the end point reflecting irreversible injury, myocardial stunning and hibernation result from reversible myocardial ischaemia-reperfusion injury, and contractile dysfunction is the obvious end point. Stunned myocardium is characterized by a disproportionately long-lasting, yet fully reversible, contractile dysfunction that follows brief bouts of myocardial ischaemia. Reperfusion precipitates a burst of reactive oxygen species formation and alterations in excitation-contraction coupling, which interact and cause the contractile dysfunction. Hibernating myocardium is characterized by reduced regional contractile function and blood flow, which both recover after reperfusion or revascularization. Short-term myocardial hibernation is an adaptation of contractile function to the reduced blood flow such that energy and substrate metabolism recover during the ongoing ischaemia. Chronic myocardial hibernation is characterized by severe morphological alterations and altered expression of metabolic and pro-survival proteins. Myocardial stunning is observed clinically and must be recognized but is rarely haemodynamically compromising and does not require treatment. Myocardial hibernation is clinically identified with the use of imaging techniques, and the myocardium recovers after revascularization. Several trials in the past two decades have challenged the superiority of revascularization over medical therapy for symptomatic relief and prognosis in patients with chronic coronary syndromes. A better understanding of the pathophysiology of myocardial stunning and hibernation is important for a more precise indication of revascularization and its consequences. Therefore, this Review summarizes the current knowledge of the pathophysiology of these characteristic reperfusion phenomena and highlights their clinical implications.
Chronic Empaglifozin treatment reduces myocardial infarct size in non-diabetic mice through STAT-3 mediated protection on microvascular endothelial cells and reduction of oxidative stress.
April 16, 2020
Empagliflozin (EMPA) demonstrates cardioprotective effects on diabetic myocardium but its infarct sparing effects in normoglyceamia remain unspecified. We investigated the acute and chronic effect of EMPA on infarct size (IS) after ischemia-reperfusion injury (I/R) and the mechanisms of cardioprotection in non-diabetic mice.
Chronic oral administration of EMPA (6 weeks) reduced myocardial IS after 30min/2h I/R (29.5%±3.0 vs 45.8%±3.2 in the control group, p<0.01). Body weight, blood pressure, glucose levels and cardiac function remained unchanged between groups. Acute administration of EMPA 24h or 4h before I/R did not affect IS. Chronic EMPA treatment led to a significant reduction of oxidative stress biomarkers. STAT-3 was activated by Y(705) phosphorylation at the 10th min of R, but remained unchanged at 2h of R and in the acute administration protocols. Proteomic analysis was employed to investigate signaling intermediates and revealed that chronic EMPA treatment regulates several pathways at reperfusion including oxidative stress and integrin related proteins which were further evaluated. Superoxide dismutase and vascular endothelial growth factor were increased throughout reperfusion. EMPA pre-treatment (24h) increased the viability of Human Microvascular Endothelial Cells in normoxia and upon 3h hypoxia/1h reoxygenation and reduced reactive oxygen species production. In EMPA treated murine hearts, CD31/VEGFR2 positive endothelial cells and the pSTAT-3(Y705) signal derived from endothelial cells were boosted at early reperfusion. INNOVATION: Chronic EMPA administration reduces IS in healthy mice via STAT-3 pathway and increased survival of endothelial cells. CONCLUSION: Chronic but not acute administration of EMPA reduces IS through STAT-3 activation independently of diabetes mellitus.